Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
08/08/2025 16:50
Atossa Therapeutics Inc ATOS.OQ ATOS.O is expected to show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025 ​LSEG's mean analyst estimate for Atossa Therapeutics Inc is for a loss of 6 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. ​ Wall Street's median 12-month price target for Atossa Therapeutics Inc is $5.50, about 86% above its last closing price of $0.77 Previous quarterly performance (using preferred earnings measure in US dollars). ​
| QUARTER ENDING | STARMINESMARTESTIMATEÂŪ | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Mar. 31 2025 | -0.05 | -0.06 | -0.05 | Beat | 11.8 |
| Dec. 31 2025 | -0.06 | -0.05 | Beat | 21 | |
| Sep. 30 2024 | -0.05 | -0.06 | -0.06 | Met | -5.9​ |
| Jun. 30 2024 | -0.06 | -0.06 | -0.05 | Beat | 11.8 |
| ​​Mar. 31 2024 | -0.07 | -0.07 | -0.05 | Beat | 25 |
| Dec. 31 2023 | -0.05 | -0.06 | -0.09 | Missed | -58.8​ |
| Sep. 30 2023 | -0.07 | -0.07 | -0.05 | Beat | 28.6 |
| Jun. 30 2023 | -0.06 | -0.08 | Missed | -33.3 |
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary